Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fei Duan

Showing results (271-280 of 276) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 276 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2026
Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary CarcinomaKai Yu, Rebecca S Tidwell, Tharakeswara K Bathala, et al.
The Lancet. Gastroenterology & Hepatology|January 22, 2022
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trialAhmed Omar Kaseb, Elshad Hasanov, Hop Sanderson Tran Cao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2021
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and NeckRenata Ferrarotto, Moran Amit, Priyadharsini Nagarajan, et al.
Nature Medicine|October 13, 2020
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinomaJianjun Gao, Neema Navai, Omar Alhalabi, et al.
Nature|October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanomaRodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature Communications|November 25, 2025
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidenceMelinda Soeung, Xinmiao Yan, Ciro Zanca, et al.
Pageof 28

Showing results (271-280 of 276) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 276 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2026
Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary CarcinomaKai Yu, Rebecca S Tidwell, Tharakeswara K Bathala, et al.
The Lancet. Gastroenterology & Hepatology|January 22, 2022
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trialAhmed Omar Kaseb, Elshad Hasanov, Hop Sanderson Tran Cao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2021
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and NeckRenata Ferrarotto, Moran Amit, Priyadharsini Nagarajan, et al.
Nature Medicine|October 13, 2020
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinomaJianjun Gao, Neema Navai, Omar Alhalabi, et al.
Nature|October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanomaRodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature Communications|November 25, 2025
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidenceMelinda Soeung, Xinmiao Yan, Ciro Zanca, et al.
Pageof 28